These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25952738)

  • 1. ¹⁸F-FDG PET/CT and Colorectal Cancer: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management.
    Marcus C; Marashdeh W; Ahn SJ; Taghipour M; Subramaniam RM
    J Nucl Med; 2015 Jul; 56(7):989-94. PubMed ID: 25952738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-FDG PET/CT and lung cancer: value of fourth and subsequent posttherapy follow-up scans for patient management.
    Marcus C; Paidpally V; Antoniou A; Zaheer A; Wahl RL; Subramaniam RM
    J Nucl Med; 2015 Feb; 56(2):204-8. PubMed ID: 25613535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-FDG PET/CT and Melanoma: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management.
    Mena E; Taghipour M; Sheikhbahaei S; Mirpour S; Xiao J; Subramaniam RM
    Clin Nucl Med; 2016 Sep; 41(9):e403-9. PubMed ID: 27355846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of 18F-FDG PET/CT to clinical assessment predicts overall survival in HNSCC: a retrospective analysis with follow-up for 12 years.
    Paidpally V; Tahari AK; Lam S; Alluri K; Marur S; Koch W; Wahl RL; Subramaniam RM
    J Nucl Med; 2013 Dec; 54(12):2039-45. PubMed ID: 24101687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorodeoxyglucose positron emission tomography/computerized tomography in differentiated thyroid cancer management: Importance of clinical justification and value in predicting survival.
    Marcus C; Antoniou A; Rahmim A; Ladenson P; Subramaniam RM
    J Med Imaging Radiat Oncol; 2015 Jun; 59(3):281-8. PubMed ID: 25676871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Follow-up or Surveillance (18)F-FDG PET/CT and Survival Outcome in Lung Cancer Patients.
    Antoniou AJ; Marcus C; Tahari AK; Wahl RL; Subramaniam RM
    J Nucl Med; 2014 Jul; 55(7):1062-8. PubMed ID: 24777290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can (18)F-FDG PET/CT scan change treatment planning and be prognostic in recurrent colorectal carcinoma? A prospective and follow-up study.
    Artiko V; Odalovic S; Sobic-Saranovic D; Petrovic M; Stojiljkovic M; Petrovic N; Kozarevic N; Grozdic-Milojevic I; Obradovic V
    Hell J Nucl Med; 2015; 18(1):35-41. PubMed ID: 25840571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of fourth and subsequent post-therapy follow-up 18F-FDG PET/CT scans in patients with breast cancer.
    Taghipour M; Sheikhbahaei S; Trahan TJ; Subramaniam RM
    Nucl Med Commun; 2016 Jun; 37(6):602-8. PubMed ID: 27110955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Indications and Impact on Management: Fourth and Subsequent Posttherapy Follow-up
    Taghipour M; Marcus C; Sheikhbahaei S; Mena E; Prasad S; Jha AK; Solnes L; Subramaniam RM
    J Nucl Med; 2017 May; 58(5):737-743. PubMed ID: 27811123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of fourth and subsequent post-treatment 18F-FDG PET/CT scans in the management of patients with non-Hodgkin's lymphoma.
    Taghipour M; Marcus C; Jones S; Sarangi R; Trahan TJ; Subramaniam RM
    Nucl Med Commun; 2016 Jul; 37(7):699-704. PubMed ID: 26990623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of follow-up FDG-PET/CT in the management and prognosis of patients with HPV-positive oropharyngeal squamous cell carcinoma.
    Taghipour M; Marcus C; Califano J; Fakhry C; Subramaniam RM
    J Med Imaging Radiat Oncol; 2015 Dec; 59(6):681-6. PubMed ID: 26768092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
    Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
    J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-FDG PET/CT: Therapy Response Assessment Interpretation (Hopkins Criteria) and Survival Outcomes in Lung Cancer Patients.
    Sheikhbahaei S; Mena E; Marcus C; Wray R; Taghipour M; Subramaniam RM
    J Nucl Med; 2016 Jun; 57(6):855-60. PubMed ID: 26837337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Follow-up FDG PET/CT in Patients With Non-Hodgkin Lymphoma: Value to Clinical Assessment and Patient Management.
    Taghipour M; Marcus C; Nunna P; Subramaniam RM
    Clin Nucl Med; 2016 Feb; 41(2):e93-7. PubMed ID: 26545018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
    Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A
    J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
    Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
    Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical impact of fluorodeoxyglucose-positron emission tomography scan/computed tomography in comparison with computed tomography on the detection of colorectal cancer recurrence.
    Deleau C; Buecher B; Rousseau C; Kraeber-Bodéré F; Flamant M; des Varannes SB; Frampas E; Galmiche JP; Matysiak-Budnik T
    Eur J Gastroenterol Hepatol; 2011 Mar; 23(3):275-81. PubMed ID: 21304319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual-time-point 18F-FDG PET/CT in patients with colorectal cancer: clinical value of early delayed scanning.
    Miyake KK; Nakamoto Y; Togashi K
    Ann Nucl Med; 2012 Jul; 26(6):492-500. PubMed ID: 22492392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-fluorodeoxyglucose PET/computed tomography and risk stratification after neoadjuvant treatment in esophageal cancer patients.
    Cervino AR; Pomerri F; Alfieri R; Sileni VC; Castoro C; Galuppo S; Evangelista L
    Nucl Med Commun; 2014 Feb; 35(2):160-8. PubMed ID: 24220054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.